Highest-materiality recent filing
Aprea Q1 net loss $3.3M ($0.22/sh); cash $46.5M; APR-1051 shows two partial responses
Cash and equivalents $46.5M as of Mar 31, 2026, up from $14.6M year-end 2025; runway into Q1 2028.
Aprea Therapeutics closes oversubscribed $30M private placement to fund APR-1051 development
Closed oversubscribed $30M private placement on March 31, 2026; proceeds for R&D and general corporate.
Aprea Therapeutics raises $30M, confirms partial response for APR-1051 in Phase 1 trial
Raised ~$30M via pre-funded warrants ($0.808) and common warrants ($0.683) expiring Dec. 31, 2029; led by Soleus Capital.
Aprea Therapeutics reports FY2025 net loss of $12.6M; APR-1051 shows two partial responses
Cash and equivalents $14.6M at Dec 31, 2025; plus Jan 2026 private placement of $5.6M funds operations into Q1 2027.
Aprea reports second partial response for APR-1051; endometrial cancer with PPP2R1A mutation
Second unconfirmed partial response (uPR) at 220 mg dose: 50% tumor shrinkage (RECIST v1.1) and CA-125 drop from 362 to 47 U/mL (-87%).
Aprea reports first partial response for APR-1051; raises $5.6M in private placement
First unconfirmed partial response (uPR) in PPP2R1A-mutated endometrial cancer at 150 mg: 50% target lesion reduction, CA-125 from 732 to 70 U/mL.
Aprea Therapeutics receives Nasdaq bid price deficiency notice; stock at risk of delisting
Closing bid below $1.00 for 30 consecutive business days triggered Nasdaq deficiency letter.
Aprea Therapeutics raises $3.1M in private placement priced at $1.165/unit
Gross proceeds ~$3.1M from 2.62M shares (or pre-funded warrants) and warrants at $1.04 exercise price.
Cash and cash equivalents $13.7M as of Sep 30, 2025; operating loss $3.1M vs $4.1M YoY.
Aprea reports 3 of 4 patients with stable disease at 100 mg APR-1051 in Phase 1 trial
3 of 4 heavily pretreated patients achieved stable disease (RECIST v1.1) at 100 mg dose level.
Aprea sets ATRN-119 RP2D at 1,100 mg QD; pauses monotherapy; prioritizes WEE1 inhibitor APR-1051
RP2D of 1,100 mg once daily identified for ATRN-119 from ABOYA-119 Phase 1/2a study.
Aprea Therapeutics Q2 net loss $0.53/sh; cash $16.5M; clinical activity in APR-1051 and ATRN-119
Cash and cash equivalents $16.5M as of June 30, 2025, down from $22.8M at Dec 31, 2024; runway into Q2 2026.
Aprea Q1 net loss $3.9M ($0.66/sh); ATRN-119 shows tumor shrinkage in 3 patients
Cash and equivalents $19.3M as of March 31, 2025, sufficient into early Q2 2026.
Aprea Therapeutics reports FY2024 net loss $13M, cash $22.8M; APR-1051 data H2 2025
Net loss of $2.9M (Q4) and $13.0M (FY2024); cash $22.8M, sufficient into Q1 2026.
Aprea Therapeutics Reports Q3 2024 Financial Results; Cash $26.2M, Net Loss $3.8M
Cash and cash equivalents of $26.2 million as of Sept 30, 2024, providing at least twelve months of runway.
Aprea reports preliminary Phase 1 safety data for WEE1 inhibitor APR-1051; no hematologic toxicity
APR-1051 safe and well-tolerated in first three patients; all adverse events Grade 1-2, no neutropenia or QT prolongation.
Aprea reports preliminary cash of $26.2M; CMO Mirza steps down, engages Dr. Pultar as advisor
Preliminary cash and equivalents ~$26.2M as of Sep 30, 2024, down from $28.7M at Jun 30, 2024.
Aprea Therapeutics reports Q2 2024 net loss of $3.5M; Phase 1 trial initiated for APR-1051
Cash $28.7M as of June 30, 2024, up from $21.6M at Dec 31, 2023; runway extended into Q4 2025.
Aprea Therapeutics Q1 net loss $2.8M; cash $32.4M; APR-1051 IND cleared; Phase 1 starts June 2024
Net loss of $2.8M ($0.67 per share) vs $4.4M ($1.34) in prior year; operating loss $3.1M down from $4.6M.
Aprea Therapeutics clears IND for APR-1051; updates on ATRN-119 Phase 1 at AACR
IND for next-gen WEE1 inhibitor APR-1051 cleared; first patient dosing expected June 2024 in Phase 1 ACESOT-1051 trial.
Cash and equivalents $21.6M at Dec 31, 2023; combined with $16M Mar 2024 private placement funds into Q3 2025.
Aprea raises up to $34M in private placement; FDA clears IND for APR-1051
$16M upfront gross proceeds from private placement; up to $18M additional from warrant exercise.
Aprea Therapeutics reports preliminary cash balance of $21.6M as of Dec 31, 2023
Preliminary cash, cash equivalents, and restricted cash expected to be approximately $21.6 million as of December 31, 2023.
ATRN-119 Phase 1/2a dose escalation shows no hematologic or liver toxicities across first three cohorts (50, 100, 200 mg) in heavily pretreated solid tumor patients.
Aprea Therapeutics Q2 net loss $3.3M; cash $27.7M; ATRN-119 data Q4 2023
Net loss $3.3M ($0.87/sh) vs $98.3M loss in Q2 2022, driven by absence of $76M IPR&D charge from Atrin deal.
Received Nasdaq approval on July 3, 2023 to transfer listing from Global Select to Capital Market.
Aprea Therapeutics reports FY2022 net loss of $112.7M; cash $28.8M, runway into Q3 2024
Cash and cash equivalents $28.8M at Dec 31, 2022, down from $53.1M; with $5.5M public offering, runway into Q3 2024.
Aprea Therapeutics discloses $1.5M SVB deposits, $28.9M in SVB-purchased money market fund
Cash deposits of approximately $1.5M held at Silicon Valley Bank (SVB) after FDIC takeover.
Aprea Therapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq deficiency letter on Sept 12, 2022 for bid price below $1.00.
On August 23, 2023, Christian S. Schade resigned from the Board of Directors (the “Board”) of Aprea Therapeutics, Inc. (the “Company”), including as Chairperson of the Board and any respective committee of the Board to which he was a member, effective immediately.
Following Mr. Schade’s resignation, on August 23, 2023, the Board appointed Richard Peters, M.D., Ph.D., to serve as Chairperson of the Board, effective immediately.
Following Mr. Schade’s resignation, on August 23, 2023, the Board appointed Dr. Jean-Pierre Bizzari as a Class III director, effective immediately
On May 5, 2023, the Board of Directors (the “Board”) of Aprea Therapeutics, Inc. (the “Company”) increased the size of the Board from eight to nine directors and appointed Gabriela Gruia, M.D., as a Class II director and new member of the Board to fill the vacancy on the Board, effective immediately, to serve until the Company’s 2024 annual meeting of stockholders or until her earlier resignation or removal.
Mr. Hamill will replace Scott Coiante, who will step down from his role as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective as of the Transition Date.
Effective January 30, 2023 (the “Transition Date”), John Hamill became Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer of Aprea Therapeutics, Inc.
Fouad Namouni and Michael A. Kelly resigned from the Board as Class II and Class III directors, respectively, and any respective committee of the Board to which they were members, effective at the Second Effective Time.
Michael Grissinger and Rif Pamukcu were appointed as Class II directors.
Michael Grissinger and Rif Pamukcu were appointed as Class II directors.
Fouad Namouni and Michael A. Kelly resigned from the Board as Class II and Class III directors, respectively, and any respective committee of the Board to which they were members, effective at the Second Effective Time.
the appointment of Greg Korbel to the position of the Chief Operating Officer of Aprea
Effective as of the conclusion of the Stockholders’ Meeting, Dr. Gilad will be appointed to the position of Chief Executive Officer of Aprea, to fill the vacancy created by Christian S. Schade’s resignation as Chief Executive Officer of Aprea
Max materiality 0.85 · Median 0.60 · Most common event other_material